Funder: METAvivor
Due Dates (Anticipated): March 2026 (Letter of Intent) | August 2026 (Invited full application) | August 2026 (Internal submission)
Funding Amounts: Up to $450,000 total over 3 years ($150,000/year max; includes direct costs and up to 5% indirect costs)
Summary: Supports advanced translational and clinical research to overcome barriers in metastatic (stage IV) breast cancer and improve patient outcomes.
Key Information: Collaboration with experienced patient advocates is required; only research addressing established metastases is eligible.